Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03193892

A National Registry on Chinese Patients With Lymphangioleiomyomatosis

A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Lymphangioleiomyomatosis (LAM-CHINA)

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,500 (estimated)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Detailed description

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China. This is a register study lasting 4 years, aims to raise 800 subjects. Primary endpoint is the annual change of forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) in pulmonary function tests.

Conditions

Timeline

Start date
2017-01-01
Primary completion
2026-10-01
Completion
2026-10-01
First posted
2017-06-21
Last updated
2021-09-24

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03193892. Inclusion in this directory is not an endorsement.